Treatment of hepatitis B e antigen-negative chronic hepatitis B with lamivudine

Journal of Hepatology

Volumn 39, Issue SUPPL. 1, 2003, Pages

  Rizzetto, Mario ^a   Marzano, Alfredo ^a   Lagget, Marco ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LACTATE DEHYDROGENASE; LAMIVUDINE; PHOSPHOTRANSFERASE;

CHRONIC HEPATITIS; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE DURATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HEPATITIS B VIRUS; HUMAN; INFECTION RISK; INTERMETHOD COMPARISON; LIVER TRANSPLANTATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SIDE EFFECT;

EID: 0141484482     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0168-8278(03)00311-8     Document Type: Conference Paper

References (28)

1. Rizzetto M. Efficacy of lamivudine in HBeAg-negative chronic hepatitis B. J Med Virol 2002;66:435-451.
2. Gaia S, Volpes R, Smedile A, Paganin S, Actis GC, Rizzetto M. Lamivudine in anti-HBeAg positive chronic hepatitis B: response after 1 year of treatment. J Hepatol 2000;32(Suppl. 2):112.
3. Buti M, Jardi R, Cotrina M, Rodriguez-Frias F, De Castro EC, Costa X, et al. Two years of lamivudine therapy in patients with chronic hepatitis B. Analysis of efficacy and emergence of HBV genomic variations. J Hepatol 2000;32(Suppl. 2):111.
4. Choi KW, Kim TN, Ju Lee H. The effect of lamivudine in Korean patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 6 months. Hepatology 2000;32:588A.
5. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 1999;29:889-896.
6. Santantonio T, Mazzola M, Iacovazzi T, Miglietta A, Guastadisegni A, Pastore G. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 2000;32:300-306.
7. Scotto G, Fazio V, Campanozzi F, D'Adduzio A. Efficacy of treatment with lamivudine in patients with chronic active e-minus variant hepatitis B virus infection: a non-randomized, open label study. Curr Ther Res 2000;62:321-330.
8. Suzuki Y, Kumada H, Ikeda K, Chayama K, Arase Y, Saitoh S, et al. Histological changes in liver biopsies after 1 year of lamivudine treatment in patients with chronic hepatitis B infection. J Hepatol 1999;30:743-748.
9. Donada C, Piva S, Faelli A, Mazzero C, Zanette G, Donadon V. Interferon alfa and lamivudine in patients with chronic anti-HBe positive hepatitis B. J Hepatol 1999;30(Suppl. 1):246.
10. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998;27:1670-1677.
11. Lau DT, Khokhar MF, Doo E, Ghany MG, Herion D, Park Y, et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000;32:828-834.
12. Rizzetto M, Santantonio T, Buti M, Heathcote J, Woessner M, Daly S, et al. Benefits of extended lamivudine treatment in patients with HBeAg-negative HBV DNA positive (pre-core mutant) chronic hepatitis B (CHB). Hepatology 2000;32:459A.
13. Esteban R. Clinical and histologic outcome of extended lamivudine in patients with HBeAg negative chronic hepatitis B (CHB). Hepatology 2001;34:1097A.
14. Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000;32:847-851.
15. Lok AS, Hussain M, Cursano C, Margotti M, Gramenzi A, Grazi GL, et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 2000;32:1145-1153.
16. Paganin S, Barbon V, Caincio A, Lagget M, Gaia S, Actis GC, et al. Long-term lamivudine monotherapy in chronic e-antigen negative hepatitis B: efficacy and breakthroughs. J Hepatol 2001;34(Suppl. 1):134.
17. Buti M, Cotrina M, Jardi R, de Castro EC, Rodriguez-Frias F, Sanchez-Avila F, et al. Two years of lamivudine therapy in anti-HBe-positive patients with chronic hepatitis B. J Viral Hepat 2001;8:270-275.
18. Papatheodoridis GV, Dimou E, Laras A, Papadimitropoulos V, Hadziyannis SJ. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002;36:219-226.
19. Tassopoulos NC, Anagnostopoulos GD, Delladetsima JK, Barbati C, Angelopoulou P, Sipsa V, et al. Extended lamivudine treatment in patients with HBeAg negative/HBV-DNA positive chronic hepatitis B (CHB). Hepatology 2000;32:456A.
20. Villeneuve JP, Condreay LD, Willems B, Pomier-Layrargues G, Fenyves D, Bilodeau M, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000;31:207-210.
21. Kapoor D, Guptan RC, Wakil SM, Kazim SN, Kaul R, Agarwal SR, et al. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol 2000;33:308-312.
22. Lampertico P, Iavarone M, Romeo R, Del Ninno E, Colombo M. Long-term lamivudine therapy improves Child-Pugh score in patients with hepatitis B-related cirrhosis. Hepatology 2000;32:458A.
23. Yao FY, Terrault NA, Freise C, Maslow L, Bass NM. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 2001;34:411-416.
24. Marzano A, Salizzoni M, Debernardi-Venon W, Smedile A, Franchello A, Ciancio A, et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001;34:903-910.
25. Honkoop P, De Man RA, Niesters HG, Zondervan PE, Schalm SW. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000;32:635-639.
26. Tatulli I, Francavilla R, Rizzo GL, Vinciguerra V, Ierardi E, Amoruso A, et al. Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B. J Hepatol 2001;35:805-810.
27. Santantonio T, Anna Niro G, Sinisi E, Leandro G, Insalata M, Guastadisegni A, et al. Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study. J Hepatol 2002;36:799-804.
28. Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000;32:129-134.